Crossject

ISIN : FR0011716265

Supergenerics

Things are getting going...hopefully

Opinion	Target Price	Upside	Price	Market Cap	Bloomberg Code	Investors Relation
Buy	€ 7.63	280%	€ 2.01	€M 83.0	ALCJ FP	Click here

Access to interactive analysis

Analyst reports

Date	Title	Research
07/10/2024	H1 24: not yet meaningful	Download
25/09/2024	H1 24: no real surprise, but a glimpse of disappointment	Download
17/07/2024	We are still believers	Download
05/06/2024	Success of the capital increase	Download
02/05/2024	We welcome the securing of the group’s financial needs	Download
03/04/2024	Patience is a virtue… hopefully	Download
28/02/2024	Securing the financing needs	Download
08/02/2024	No news is not always good news...	Download
06/01/2024	Marketing initiative in the US	Download
03/01/2024	A new distribution agreement in Northern Europe	Download
28/09/2023	H1 23: no surprises before the release of the detailed accounts in October	Download
27/03/2023	No real news in the FY22 results.	Download
23/03/2023	FY22: not much to learn from the release	Download
12/01/2023	Crossject has announced it has raised €14m in debt to finance its expansion.	Download
26/09/2022	Minor changes after H1 22	Download
23/09/2022	A rather reassuring H1 22	Download
05/09/2022	Adjusting our forecasts to the new number of shares	Download
25/07/2022	The update of our assumptions confirms a huge upside potential	Download
22/07/2022	The update of our assumptions confirms a huge upside potential	Download
20/06/2022	A major breakthrough for Crossject	Download
29/03/2022	FY21: not very meaningful, as expected	Download
17/12/2021	New financing	Download
24/09/2021	H1 21: unsurprising (as usual)	Download
31/08/2021	We have fine-tuned our numbers on the back of the FY20 detailed accounts. Forecasts were also partly amended but net results remain low in the next few years which explains why a small change in the e	Download
18/08/2021	We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before	Download
18/06/2021	Another good piece of news for the group	Download
17/06/2021	A licensing agreement for Zeneo Hydrocortisone in the US and Canada	Download
31/03/2021	FY20 unsuprising; waiting for more	Download
15/12/2020	A double bond issue	Download
21/09/2020	Update on the group's business	Download
22/05/2020	No major changes after the release of the FY19 report	Download
29/03/2020	Meaningless FY19 results and product update	Download
23/12/2019	Extra-financing to increase visibility	Download
20/11/2019	A €2.6m non-dilutive issue	Download
15/10/2019	Cooperation agreement with the US Department of Defense	Download
10/09/2019	H1 19: no surprise	Download
10/07/2019	Warrants to existing shareholders	Download
19/06/2019	A commercial success	Download
18/04/2019	The 2018 bonds fully converted	Download
18/03/2019	No major change post FY18 results	Download
15/03/2019	Slowly but surely	Download
04/02/2019	Some extra non-dilutive financing	Download
24/12/2018	Adjustment in the number of shares	Download
21/12/2018	Success of the capital increase	Download
29/11/2018	A €3.9m capital increase before year-end	Download
28/11/2018	A €3.9m capital increase	Download
22/11/2018	Excellent news: production has resumed	Download
23/10/2018	Bond conversion	Download
03/10/2018	The delayed launch of Zeneo implies a lower target price	Download
27/09/2018	H1 18: insignificant; some more time needed to reach the market	Download
05/09/2018	On its way to reaching the market	Download
13/07/2018	A convertible bond and potential options for existing shareholders	Download
17/05/2018	Business update	Download
22/03/2018	On its way to reach the market…	Download
14/02/2018	A convertible bond and options for existing shareholders	Download
03/02/2018	Orphan disease status for Zeneo® Midazolam in the US	Download
11/12/2017	Update on the company’s activities	Download
25/09/2017	H1 17: a new NTE in the pipeline...and further delays	Download
06/04/2017	The capital increase was successful	Download
14/03/2017	New valuation after the ongoing capital increase	Download
13/03/2017	FY16 results - untelling (as expected) and a €4.3m capital increase	Download
24/11/2016	A strategic review… and some adjustments to our forecasts	Download
23/11/2016	A strategic review….and a few questions	Download
20/09/2016	H1 16 results: not very telling as expected	Download
29/08/2016	When apparent threats are also opportunities	Download
25/02/2016	Initiating coverage of Crossject.	Download